BJC

British Journal of Cancer (2015) 113, 1397–1404 | doi: 10.1038/bjc.2015.312

Keywords: cancer; place of death; death certificates; end-of-life care; cross-national comparison

International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data

J Cohen^{*,1,15}, L Pivodic^{1,15}, G Miccinesi², B D Onwuteaka-Philipsen³, W A Naylor⁴, D M Wilson⁵, M Loucka⁶, A Csikos⁷, K Pardon¹, L Van den Block¹, M Ruiz-Ramos⁸, M Cardenas-Turanzas⁹, Y Rhee¹⁰, R Aubry¹¹, K Hunt¹², J Teno¹³, D Houttekier^{1,16} and L Deliens^{1,14,16}

¹Department of Family Medicine & Chronic Care, End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Laarbeeklaan 103, 1090 Brussels, Belgium; ²ISPO Cancer Prevention and Research Institute, Clinical Epidemiology Unit, Via Oblate 2, Pal 28/A, 50142 Florence, Italy; ³Department of Public and Occupational Health, EMGO+ Institute for Health and Care Research, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands; ⁴Hospice Waikato, 334 Cobham Drive, Hillcrest, Hamilton 3216, New Zealand; ⁵Faculty of Nursing, University of Alberta, 11405 87 Avenue, Edmonton, Alberta T6G 1C9, Canada; ⁶Center for Palliative Care, Michelska 1/7, Prague 140 00, Czech Republic; ⁷University of Pécs Medical School, 48-as tér 1, 7622 Pécs, Hungary; ⁸Information and Evaluation Service, Regional Ministry of Health in Andalusia, Av. Innovación, s/n - Edificio Arenas 1, 41071 Seville, Spain; ⁹Department of General Internal Medicine, MD Anderson Cancer Center, The University of Texas, Houston, 515 Holcombe Blvd, Houston, TX 77030, USA; ¹⁰Department of Health Science, Dongduk Women's University, 23-1 Hawolgok-dong, Seongbuk-gu, Seoul, South Korea; ¹¹French National Observatory on End-of-Life Care, 35 Rue du Plateau, 75952 Paris CEDEX 19, France; ¹²Faculty of Health Sciences, University of Southampton, 104 Burgess Road, Southampton SO17 1BJ, Hampshire, UK; ¹³Cambia Palliative Care Center of Excellence, University of Washington Division of Geriatric Medicine, Box 359765, 401 Broadway, Suite 5123.11 Seattle, WA 98122, USA and ¹⁴Department of Medical Oncology, Ghent University Hospital, De Pintelaan 185, Building 6K12E, 9000 Ghent, Belgium

Background: Where people die can influence a number of indicators of the quality of dying. We aimed to describe the place of death of people with cancer and its associations with clinical, socio-demographic and healthcare supply characteristics in 14 countries.

Methods: Cross-sectional study using death certificate data for all deaths from cancer (ICD-10 codes C00-C97) in 2008 in Belgium, Canada, Czech Republic, England, France, Hungary, Italy, Mexico, the Netherlands, New Zealand, South Korea, Spain (2010), USA (2007) and Wales (N = 1.355910). Multivariable logistic regression analyses evaluated factors associated with home death within countries and differences across countries.

Results: Between 12% (South Korea) and 57% (Mexico) of cancer deaths occurred at home; between 26% (Netherlands, New Zealand) and 87% (South Korea) occurred in hospital. The large between-country differences in home or hospital deaths were partly explained by differences in availability of hospital- and long-term care beds and general practitioners. Haematologic rather than solid cancer (odds ratios (ORs) 1.29–3.17) and being married rather than divorced (ORs 1.17–2.54) were most consistently associated with home death across countries.

Conclusions: A large country variation in the place of death can partly be explained by countries' healthcare resources. Country-specific choices regarding the organisation of end-of-life cancer care likely explain an additional part. These findings indicate the further challenge to evaluate how different specific policies can influence place of death patterns.

Received 17 March 2015; revised 8 July 2015; accepted 10 August 2015; published online 1 September 2015

© 2015 Cancer Research UK. All rights reserved 0007-0920/15

^{*}Correspondence: Professor J Cohen; E-mail: jcohen@vub.ac.be

¹⁵These authors contributed equally to the manuscript.

¹⁶These authors contributed equally as last author to the manuscript.

Although life extension and outright cures are possible now for many types of cancers, it remains one of the leading causes of death worldwide. Advanced cancer patients form a large group among people who could benefit from a care approach aimed at comfort and quality of life (Smith et al, 2012). One important aspect of this approach is respect for patient choices in terms of the places where they receive ongoing care, spend the last days of their lives and ultimately die (Davies and Higginson, 2004). Evidence across many studies suggests that, for the majority of people with cancer and their caregivers, home is the preferred place of death (Gomes *et al*, 2013). Previous research indicates that dying in one's home environment is better aligned with patient's well-being as it benefits control, autonomy, dignity and continuity of care and involves lower healthcare costs and less risk of iatrogenic events and overly aggressive treatments (Marie Curie Cancer Care, 2012; Higginson et al, 2013; Boockvar et al, 2014).

At the population level, place of death is a valid indicator of where care is provided in the final hours or days of life (Earle, 2003). Cancer is a leading cause of death worldwide, and so knowing where people with cancer die and understanding the determinants of dying in a particular place are important public health issues, relevant not only to a commitment to patient preferences but also to efforts to avoid unnecessary hospitalisations (House of Commons Health Committee, 2004; Federale Evaluatiecel Palliatieve Zorg, 2008; Pennec *et al*, 2013). Several countries have developed policies and programmes to strengthen palliative and end-of-life care at home and to facilitate dying in the place of choice (Department of Health, 2008; Wright *et al*, 2008; Van Beek *et al*, 2013).

Population-level monitoring of place of death trends provides descriptive information that, if complemented with more in-depth understanding, can help inform public health policy regarding the allocation of end-of-life care resources and to support improvement strategies. Adding a cross-national comparison provides an opportunity to examine differences in place of death between countries with different levels of palliative care integration and different policies related to, amongst others, cancer care, long-term care and end-of-life care. This can help generate hypotheses regarding the influence of different factors related to policy and healthcare organisation and strategies for influencing where people die (Hantrais, 2008). Although previous studies have looked at cross-national differences in place of death in Europe (Cohen *et al*, 2010; Houttekier *et al*, 2010), no studies using individual data have made comparisons across continents.

The aim of this study was to describe the place of death of cancer patients and associated characteristics in 14 countries across 4 continents. We investigated where people with cancer die in 14 countries across 4 continents and how this differs from where people with a non-cancer condition die, to what extent differences in patient characteristics and healthcare supply explain variations between countries in place of death and to what extent the place of death of cancer patients is associated with patient characteristics and healthcare studied.

MATERIALS AND METHODS

Study design. This study is part of the International Place of Death project, which collected complete death certificate data for a period of 1 year in 14 countries (Table 1). We obtained full country data except for Spain, where the data are from the Andalusia province, and Canada where the data do not include the Quebec province. An exploration of all candidate partners showed that, at the time of the data collection (2011–2013), 2008 was the most recent year for which data were available in most targeted countries. In the USA, 2007 was the most recent available year

and in Andalusia (Spain), place of death was not recorded before 2010. We also obtained a number of clinical, socio-demographic and residential characteristics of the deceased, factors already identified as being associated with the place of death in people with cancer.(Gomes and Higginson, 2006) The project lead coordinated all data requests to ensure similar variables and data and pooled all data into one common database. Ethics approval was not required as we studied anonymised death certificate data.

Data. All included countries have similar death certification: generally the attending physician certifies the sex of the deceased, the cause or causes of death and the day and place of death. The authorities in each country check these certificates for inconsistencies and code death causes according to the WHO's International Classification of Diseases 10th Revision (ICD-10). The death certificates of some countries contain socio-demographic information, while in other countries it can be gained through links with other databases (e.g., census data). A minimum number of socio-demographic variables were thus obtained. Available healthcare regions within the countries studied and linked to the region of residence of each deceased cancer patient (Supplementary Table S1, Supplementary Material).

Measures. The place of death was derived from the death certificate and comprised at minimum the categories home, hospital and nursing home/care home in all countries except Hungary where only hospital and other location were distinguished and Mexico where nursing home/care home is not a recorded category because there are no such facilities. We henceforth refer to nursing home/care as 'long-term care facility'.

As independent variables we included individual sociodemographic (age, sex, marital status) and clinical characteristics (dying from cancer, including respiratory, gastrointestinal, genitourinary, haematologic and other cancers, or from a noncancer condition excluding deaths from external causes such as accident and homicide), degree of urbanisation of the region of residence and healthcare supply measures that were identified as relevant in the literature on place of death of people with cancer (Gomes and Higginson, 2006). The codes of the municipality/local authority of residence were matched with available data on urbanisation levels and healthcare supply. The healthcare supply data included the number of hospital beds per 10 000 inhabitants, the number of family physicians or general practitioners per 10000 inhabitants and the number of long-term care beds per 1000 inhabitants aged 65 years or over, each per health region of residence of the deceased. In some countries, the individual's region of residence was not identified. For those countries we used nationally aggregated measures of healthcare supply.

Statistical analysis. In the 14 countries all deaths with cancer as an underlying or primary cause of death (ICD-10 codes C00-C97) were selected. The cause of death was recorded as solid *vs* haematological cancer. Descriptive statistics were used to describe the place of death. Relative risks (unadjusted risk ratios) were calculated to compare the chances of dying in a certain setting for those with cancer and all those without cancer (excluding deaths from external causes).

To evaluate to what extent the country differences in place of death could be accounted for by clinical and socio-demographic characteristics or healthcare supply, a hierarchical binary logistic regression using all cancer deaths with place of death (home *vs* elsewhere) as the dependent variable and country as an independent variable (Model 1) was expanded by entering cancer type (18 types of cancer), age, sex and marital status (Model 2), and then density of hospital beds, long-term beds and general practitioners (Model 3) into the model. This method was chosen

Table 1. Deaths from cancer and socio-demographic characteristics in 2008^a in 14 countries

				-	Type of car	ncer (% of all de	eaths)				Aae	
							,			(% (of all ca	ncer
										,	deaths	
			Deaths from						Sex		1	
		Total	cancer						(% of all			80
		number of	N (% of all		Gastro-		Haemato-		cancer deaths			and
Country	Abbreviations	deaths	deaths)	Respiratory	intestinal	Genitourinary	logical	other	% women	0–59	60–79	above
Continental We	stern Europe											-
France	FR	541 135	153 576 (28 4)	5.8	8.5	4.6	24	71	41.2	19.3	47.4	33.4
Italy	IT	578 192	164 297 (28.4)	6.1	9.8	4.1	2.4	6.0	43.3	13.1	51.7	35.3
Spain (Andalusia) ^a	ES	57 380	15 194 (26.5)	6.1	8.6	4.8	1.9	5.1	36.9	18.4	52.6	29.0
Belaium	BE	102 924	26749 (26.0)	6.6	7.1	4.1	2.1	6.1	43.4	17.0	50.7	32.4
Netherlands	NL	135 136	40750 (30.2)	7.5	9.0	5.0	2.2	6.4	46.3	18.0	52.6	29.4
Central/Eastern	Europe											-
Czech Republic		101 804	26,996 (26,5)	5.6	8.8	4 7	17	5.8	44.4	19.9	57.2	22.9
Hungary	HU	130 027	32 111 (24.7)	6.9	8.0	3.4	1.4	5.0	44.3	27.2	53.5	19.3
UK								I				
England	ENG	475763	128 802 (27.1)	6.1	7.6	4.7	2.1	6.6	47.7	13.7	50.9	35.4
Wales	WAL	32 066	8681 (27.1)	6.5	7.8	4.5	2.0	6.3	47.0	13.1	52.2	34.6
Oceania							I	1				
New Zealand	NZ	29312	8454 (28.8)	5.8	8.8	4.9	2.6	6.8	46.8	17.9	51.1	31.0
North America		IJ					1	1				-
Canada ^b	CA	182 134	51 622 (28.3)	7.3	7.7	4.4	2.6	6.4	47.3	17.9	49.9	32.2
United States ^a	US	2 428 342	563 569 (23.2)	6.7	5.6	3.5	2.3	5.1	48.0	20.6	49.6	29.8
Latin America							I	1				
Mexico	MX	528093	65 812 (12.5)	1.4	4.0	2.8	1.4	2.9	51.0	35.5	45.8	18.8
East Asia		IJ					1	1				
South Korea	KR	247 757	69 297 (28.0)	6.3	15.3	2.2	1.4	2.8	36.4	26.2	56.7	17.0
Total		5 570 065	1 355 910 (24.3)									
Percentages may not ^a Reference year is 20	add up to total du 07 in USA and 2010	e to rounding.) in Spain (And	alusia).									

^bThe data for Canada exclude the province of Quebec.

as it allows evaluating how certain groups of variables explain part of the variation between countries.

To evaluate to what extent the place of death of cancer patients was associated with patient characteristics and healthcare supply in each of the countries studied a multivariable binary logistic regression analysis (home *vs* elsewhere) for all cancer patients was conducted for each country with various independent candidate variables (see Supplementary Material for more information).

All models were checked for multicollinearity by looking at tolerance values and variance inflation factors. Analyses were done in IBM SPSS Statistics 22.

RESULTS

Population and healthcare availability per country. In the countries studied, between 13% (Mexico) and 30% (Netherlands) of all deaths had cancer listed as the underlying cause (Table 1). The percentage of women among those who died of cancer was slightly less than 50% in all countries except Mexico; in all countries around half died between the age of 60 and 79; around one-third died at the age of 80 or over except in Mexico (19%) and South Korea (17%). Mexico was the only country where more than one-third (35%) died between the age of 0 and 59. Between 51% (US) and 65% (South Korea) of those who died of cancer had been married (Supplementary Table S2, Supplementary Material). A relatively high number of beds (more than 70 per 10000 population) existed in hospitals in Korea, Hungary, France, Czech Republic and Belgium, while a relatively high number of long-term care beds (more than 70 per 1000 population aged 65 or over)

existed in the Netherlands, New Zealand and Belgium (Supplementary Table S3, Supplementary Material).

Place of death per country. Between 12% (Korea) and 56% (Mexico) of people who died of cancer died at home. The largest proportion of home deaths was in Mexico, followed by the Netherlands (46%), Italy (45%) and USA (39%). Deaths in hospital ranged from 26% in the Netherlands and New Zealand to 87% in Korea (Table 2).

As compared with persons dying from natural non-cancer conditions, those dying from cancer had a higher probability of dying at home in most countries except France, Spain, the Czech Republic and Korea (Table 2); but they also had a higher probability of dying in hospital in France, Spain, Belgium Czech Republic, Hungary, Canada and South Korea. In all countries, those who died of cancer were less likely to die in a long-term care facility than those who died of non-malignant causes. People with cancer also had a higher probability of dying in a palliative care institution (in countries where such a place was registered) than did those who died from non-cancer conditions, although this difference was much smaller in the United States (unadjusted relative risk (RR) = 2.52) and the Netherlands (RR = 4.06) than in England (RR = 28.67), Wales (RR = 32.00) and New Zealand (RR = 14.54).

Multivariable analysis aimed at explaining country variation in home deaths. The country differences in the likelihood of dying at home *vs* another location (Model 1) remained largely unchanged when we controlled for differences between countries in cause of death, age and sex (Model 2; Figure 1; odds ratios (ORs) and 95% confidence intervals (CI) at each step of analysis in Supplementary Table S4, Supplementary Material). However, when the density of

Table 2. The place of	death of cance	r and r	non-cai	ncer d	eaths i	n 14 c	ountrie	es duri	ng 200	8					
	Place of death	FR	IT	ES	BE	NL	CZ	HU	ENG	WAL	NZ	CA	US	MX	KR
Cancer	Home	19.1	45.3	31.6	28.9	46.3	18.2	/ ^a	26.1	26.2	28.5	16.1	39.0	57.3	11.8
	Hospital	72.8	47.3	64.9	59.3	25.8	64.7	67.7	44.4	56.6	26.2	67.6	33.7	39.9	87.2
	Nursing home	5.5	3.9	3.3	11.2	19.3	16.6	/ ^a	10.9	6.0	24.0	11.4	16.3	/ ^a	0.8
	PC institutions	/ ^a	/ ^a	/ ^a	/ ^a	7.3	/ ^a	/ ^a	17.2	9.6	18.9	/ ^a	5.3	/ ^a	/ ^a
	Others	2.7	3.5	0.2	0.6	1.4	0.5	32.3	1.4	1.6	2.5	5.0	5.8	2.7	0.2
Non-cancer patients ^b	Home	29.4	41.1	34.9	21.0	18.8	22.5	/ ^a	17.3	17.1	18.8	13.3	20.8	45.9	27.9
	Hospital	52.7	46.9	54.8	48.4	33.5	56.1	61.3	59.8	65.4	38.1	59.4	47.6	50.4	68.5
	Nursing home	13.9	7.6	9.6	29.1	42.0	18.9	/ ^a	20.7	15.2	36.4	22.7	25.6	/ ^a	2.2
	PC institutions	/ ^a	/ ^a	/ ^a	/ ^a	1.8	/ ^a	/ ^a	0.6	0.3	1.3	/ ^a	2.1	/ ^a	/ ^a
	Others	4.1	4.4	0.7	1.5	3.9	2.5	38.7	1.7	2.1	5.4	4.5	3.9	3.7	1.3
Unadjusted relative risks:	Home	0.65	1.10	0.91	1.38	2.46	0.81	/ ^a	1.51	1.53	1.52	1.21	1.88	1.25	0.42
(Cancer vs non-cancer)	Hospital	1.38	1.01	1.18	1.23	0.77	1.15	1.10	0.74	0.87	0.69	1.14	0.71	0.79	1.27
	Nursing home	0.40	0.51	0.34	0.38	0.46	0.88	/ ^a	0.53	0.39	0.66	0.50	0.64	/ ^a	0.36
	PC institutions	/ ^a	/ ^a	/ ^a	/ ^a	4.06	/ ^a	/ ^a	28.67	32.00	14.54	/ ^a	2.52	/ ^a	/ ^a
	Others	0.66	0.80	0.29	0.40	0.36	0.20	0.83	0.82	0.76	0.46	1.11	1.49	0.73	0.15
Alalana datana DE Dalatana (la Dava da	L. ENIC	En el en el		-in ED	English and L	III II	TI	Hall IZD	Caustle 1/	NAV	N 4	. NIL NI	بامعتما ومعام

Abbreviations: BE = Belgium; CA = Canada; CZ = Czech Republic; ENG = England; ES = Spain; FR = France; HU = Hungary; IT = Italy; KR = South Korea; MX = Mexico; NL = Netherland; NZ = New Zealand; PC = palliative care; US = United States; WAL = Wales. Missing data for place of death: Korea (0.1%), USA (0.2%), Czech Republic (0.8%), Italy (4.8%) and Mexico (4.9%). ^aLocation not recorded on death certificates.

 ${}^{\mathbf{b}}\mathsf{Excludes}$ all deaths from external causes.

hospital and long-term care beds and the density of general practitioners per health region were added to the model (i.e., assuming a similar density of available healthcare resources; Model 3), a larger part of the differences was explained as the difference in the chances of dying at home between France (reference category) and several other countries was reduced. Controlling for all covariates, the chances of dying at home still remained higher in Italy, Belgium, the Netherlands, New Zealand, the United States and Mexico as compared with France.

Factors associated with death at home within each country. When the effects of socio-demographic and healthcare supply factors were adjusted for, a death from a solid tumour was in all countries more likely to occur at home than a death from a haematologic cancer, although the difference was larger in some countries than others (e.g., OR = 3.17 (95% CI 2.99-3.35) in Mexico, OR = 1.29 (95% CI 1.14-1.46) in South Korea; Table 3). The chances of dying at home gradually increased with age in France, Italy, Spain, Mexico and Korea but decreased with age in all other countries (except Czech Republic where no clear age pattern emerged). In all countries married people were more likely to die at home compared with the divorced, unmarried and widowed. In all European countries with educational attainment data available (Italy, Spain, Belgium and Czech Republic), those with higher educational attainment had better chances of dying at home than those with lower educational attainment. In the USA, no clear differences by educational attainment were found, and in Mexico and Korea an opposite pattern was found; those with higher educational attainment had lower chances of dying at home. A lower degree of urbanisation was related to higher chances of a cancer death at home, except in Canada and France where the opposite was true. The chances of dying at home decreased with an increasing density of hospital beds in France, Italy, Belgium, USA, Canada and Mexico, with the largest effect found in Italy. No clear association was found across countries between the chances of dying at home and the density of long-term care beds or the density of general practitioners per region of residence. The regression models explained a small proportion of the variation in dying at home vs elsewhere (R^2 range from 0.02 in Czech Republic to 0.21 in Italy).

DISCUSSION

Our study found a strikingly large variation across 14 countries in the place of death of people with cancer, especially in the extent to which home (percentages ranging from 12 to 57%) or hospital (percentages ranging from 26 to 87%) was the place of death. These large country differences were explained only to a limited extent by demographic differences (age, sex), cancer site and healthcare supply (rate of hospital beds, long-term care beds and general practitioners per health region), which indicates that a large part of the variation between countries is attributable to other factors. There were also notable differences between countries in the strength and direction of associations between various factors (e.g., age) and the chances of dying at home, while some factors were consistently associated with home death in the same direction (e.g., solid *vs* nonsolid tumour and marital status).

To our knowledge, this is the largest cross-national study on the place of death of people who died from cancer, having examined over 1.3 million deaths in 14 countries on 4 continents. Death certificate data have the major advantage that they provide population-level data that do not suffer from potential bias inherent to samples, and ensure good statistical power to evaluate a larger number of associated factors. Similarities in death certification and cause of death coding make the pooling of the individual country data for cross-national analysis both feasible and reliable. They also entail a number of limitations. Inaccuracies in cause of death recording through death certificates have been reported (O'Sullivan, 2011). With regard to cancer, this mainly concerns site-specific accuracy rather than causes other than cancer being recorded (Lund et al, 2010). Our use of aggregated cause of death categories (solid vs haematological cancer) may have mitigated this problem. Coding of place of death is not uniform across countries (i.e., categories like hospice/palliative care institution in most countries are missing and in Hungary only hospital vs outside hospital is coded), and this reaffirms previous calls for more standardisation and completeness in place of death coding on death certificates (Cohen et al, 2007; Pivodic et al, 2013). Death certificate data do not provide all important factors known to influence place of death (Gomes and Higginson, 2006). Information needed to estimate the clinical predictability of dying in a certain care setting, such as detailed clinical events and symptoms, is not provided and death certificates do not shed light on the reasons for hospitalisation at the very end of life (Cohen et al, 2007). Differences between countries in these factors may have been able to explain an additional part of the country differences in place of death. Another limitation is that the same set of variables potentially associated with place of death is not available in all countries (e.g., hospital bed availability per healthcare region). However, an evaluation of the influence of the omission of factors in some countries indicated that these only marginally affected the



Figure 1. Country differences (ORs) in home death (vs other), accounting for socio-demographic factors, cause of death and healthcare supply. Hierarchical binary logistic regression analyses with home vs all other places of death as dependent variable. France is the reference category in the independent variable country. Independent variables: Model 1: country (reference category: France); Model 2: additionally sex, age, cancer site (17 categories: head and neck; stomach; colon, rectum and anus; pancreas; other gastrointestinal; trachea, bronchus and lung; other respiratory; breast; cervix uteri, corpus uteri and ovary; prostate; urinary tract; other genitourinary; central nervous system; Non-Hodgkin's lymphoma; leukaemia; and other haematologic malignancies); Model 3: additionally number of hospital beds per 1000 inhabitants, long-term care beds per 1000 inhabitants, and general practitioners per 10000 inhabitants in the region of residence. Comparing the three models allows evaluating whether certain variables explain part of the variation between countries. ORs getting closer to each other and closer to 1 when independent variables. For many countries this is particularly the case in Model 3, which indicates that the variables entered in Model 3 explain part of the variation (more than the ones entered in Model 2). Model 3 provides the ORs for home death of the different countries as compared with France in case the density of available health resources was the same as in France. In some countries (Spain, England and Wales) the larger ORs compared with France became smaller than 1, which suggests that if these countries healthcare supply as in France the home death rate could be expected to be lower than in France. However, a large part of the variation between countries remained unexplained and thus needs to be attributed to other factors.

ORs of the other variables in the multivariable analysis. We therefore believe that the effects of different factors within a country can be compared between countries. Conceptual equivalence is a common issue in cross-national comparative research. In our study, acute hospitals and long-term care settings can have different characteristics in different countries, and this should be kept in mind when interpreting the country differences in place of death, controlled for availability of hospital beds, long-term care beds and general practitioners.

Although caution not to overinterpret the found country differences is necessary and multiple complex reasons can underlie these differences, they do present real differences in terms of where similar patients spend their final hours. The statistical patterns of place of death across the different countries can be interpreted as empirical indications of the way in which each country manages end-of-life care. The findings of this study provide two important types of information for addressing some of the public health challenges related to end-of-life cancer care. Firstly, the findings inform decisions regarding the allocation of end-of-life cancer care resources, support and improvement strategies. In some countries, notably France, Spain, Belgium, Czech Republic, Hungary, Canada and Korea (countries with 60% or more of cancer deaths occurring in hospital), the hospital appears to have an important role in terminal cancer care. In other countries, notably Italy, the Netherlands, the USA and Mexico, the home setting has a more prominent role. Although high quality terminal care needs to be

promoted and safeguarded in all care settings, the findings imply that some countries should primarily focus on evaluating and, if needed, improving resources for terminal cancer care in hospitals, while the focus in other countries should be the home setting. In countries where a high percentage of people with cancer die at home, such as Mexico, where this is likely to be due to issues of accessing (institutional) healthcare and where dying at home may imply dying without professional support (Cárdenas-Turanzas et al, 2011), guaranteeing a 'good death' at home is a major public health challenge. Our findings also illustrate that, although long-term care facilities are often overlooked as places for cancer care (Fennell, 2009), they are important places of death for people with cancer in some countries (e.g., Netherlands and New Zealand). It is important therefore to ensure that terminal and end-of-life care in those settings meets the specific needs of those with cancer.

Secondly, our findings highlight factors that could potentially influence place of death patterns. Country variation in place of death can to a certain degree be attributed to the availability of hospital and long-term care beds or general practitioners. However, a large part of the country variation in place of death remained unexplained. A review of country-level data for contextual explanation of the differences did not show any clear association between country patterns of place of death and their health expenditure or social expenditure as a percentage of the GDP, nor the availability of palliative care resources

Table 3. Multivariał	ple logistic re	egression me	pdels ^a per c	puntry of fac	tors associate	ed with hom	le death vs o	ther					
							OR (95% CI	(
	R	F	ES	BE	NL	Ŋ	ENG	WAL	NZ	CA	N	MX	KR
Cases included in analysis	152761 ^b	73 042 ^b	13255 ^b	16059 ^b	40750 ^b	24 321 ^b	119 394 ^b	8016 ^b	8454 ^b	50038 ^b	554 917 ^b	61279 ^b	68 1 30 ^b
Cancer site													
Solid (vs haematologic)	1.39 (1.32–1.46)	1.92 (1.84–2.00)	1.95 (1.65–2.30)	2.05 (1.75–2.39)	1.84 (1.70–2.00)	1.91 (1.61–2.25)	1.82 (1.72–1.92)	1.82 (1.46–2.26)	1.44 (1.20–1.73)	1.64 (1.49–1.81)	1.81 (1.78–1.85)	3.17 (2.99–3.35)	1.29 (1.14–1.46)
Sex													
Female (vs male)	ns	0.89 (0.87-0.91)	0.93 (0.85–1.01)	1.09 (1.01–1.18)	1.05 (1.00–1.09)	1.09 (1.01–1.17)	1.03 (1.00–1.06)	su	su	su	0.98 (0.96–0.99)	0.96 (0.93–1.00)	1.30 (1.23–1.38)
Age													
0-49	0.40 (0.37–0.44)	0.48 (0.45–0.52)	0.24 (0.19-0.31)	1.62 (1.27–2.08)	3.42 (2.98–3.93)	0.89 (0.67–1.18)	1.75 (1.60–1.91)	2.02 (1.42-2.87)	4.37 (3.14-6.06)	1.86 (1.59–2.18)	1.29 (1.24–1.33)	0.33 (0.29–0.37)	0.26 (0.21-0.31)
50-59 60-69	0.43 (0.40–0.46) 0.44 (0.42–0.47)	0.52 (0.49–0.56) 0.57 (0.54–0.60)	0.26 (0.21–0.32) 0.31 (0.25–0.38)	1.22 (0.98–1.53) 1.12 (0.91–1.38)	2.82 (2.49–3.19) 2.54 (2.26–2.86)	0.25 (0.59-0.97)	1.78 (1.65–1.92) 1.74 (1.63–1.87)	1.97 (1.45–2.66) 1.89 (1.44–2.50)	3.94 (2.89–5.37) 3.88 (2.88–5.21)	2.01 (1.75–2.32) 1.77 (1.55–2.02)	1.34 (1.30–1.38) 1.35 (1.31–1.38)	0.37 (0.33-0.42) 0.42 (0.38-0.47)	0.31 (0.26–0.37) 0.45 (0.38–0.53)
70–79	0.48 (0.45–0.51)	0.67 (0.63-0.70)	0.48 (0.40-0.58)	1.04 (0.84–1.27)	2.04 (1.82–2.29)	0.77 (0.61-0.99)	1.59 (1.49–1.70)	1.68 (1.29–2.19)	2.80 (2.08–3.75)	1.54 (1.35–1.75)	1.31 (1.27–1.34)	0.53 (0.47-0.60)	0.66 (0.56-0.77)
80–89 90 and older	0.62 (0.59–0.66) ref	0.80 (0.76–0.84) ref	0.73 (0.61–0.88) ref	1.05 (0.85–1.28) ref	1.49 (1.33–1.68) ref	0.80 (0.63–1.02) ref	1.35 (1.27–1.44) ref	1.43 (1.09–1.86) ref	1.91 (1.41–2.57) ref	1.38 (1.21–1.56) ref	1.18 (1.14–1.21) ref	0.70 (0.62–0.78) ref	0.84 (0.71–0.99) ref
Marital status										-			
Inmarriad	1 10 (1 03-1 17)	1 21 (1 11_1 33)	1 00 (0 77-1 31)	1 04 (0 86-1 26)	faf	1 28 (1 06-1 54)	0 79 (0 74-0 84)	0 63 (0 48-0 83)	υ	1 13 (0 99–1 28)	0.75 /0.73_0.77)	U C	1 07 (0 87_1 30)
Married	1.49 (1.41–1.56)	2.07 (1.90–2.26)	1.17 (0.92–1.49)	1.99 (1.73–2.28)	2.54 (2.43–2.65)	1.86 (1.66–2.10)	1.79 (1.71–1.88)	1.76 (1.47–2.11)	υ	1.76 (1.60–1.94)	1.72 (1.69–1.75)	SU	1.39 (1.22–1.60)
Widowed	1.01 (0.95–1.07) ref	1.63 (1.49–1.78) ref	1.07 (0.83–1.38) ref	0.91 (0.78–1.07) ref	υυ	1.46 (1.27–1.67) ref	1.03 (0.97–1.08) ref	1.01 (0.83–1.24) ref	υυ	1.33 (1.19–1.48) ref	1.22 (1.19–1.24) ref	ns c	1.09 (0.94–1.27) ref
Educational attainme	ent												
				7.0		7	U	U	U		J	J	1
Primary or less Lower secondary Higher secondary Hicher		ref 1.01 (0.98–1.05) 1.15 (1.10–1.20) 1.28 (1.20–1.37)	ret 0.95 (0.86–1.04) 0.98 (0.88–1.09) 1 26 (1 06–1 50)	ret 1.22 (1.11–1.34) 0.93 (0.84–1.02) 1.46 (1.28–1.65)		ret 1.00 (0.92–1.08) 1.08 (0.97–1.21) 1 47 (1 24–1 74)					ret 0.96 (0.93–0.99) 0.93 (0.91–0.95) 0.98 (0.95–1.00)	ret 0.58 (0.52–0.65) 0.76 (0.71–0.80) 0.62 (0.59–0.65)	ret c 0.73 (0.69–0.77) 0 55 (0.50–0.61)
Urbanisation													
Strong	ref	ref	ref	ref	ref	υι	ref	su	υι	ref			ref
Average Rural	0.81 (0.79–0.84) 0.91 (0.88–0.95)	1.19 (1.15–1.22) 1.35 (1.32–1.39)	1.89 (1.74–2.05) 1.78 (1.52–2.08)	1.40 (1.29–1.52) 1.47 (1.32–1.63)	1.18 (1.11–1.24) 1.50 (1.44–1.57)	υυ	1.24 (1.20–1.28) 1.41 (1.28–1.55)	n Sn	υυ	0.93 (0.87–0.99)			0.87 (0.79–0.95) 1.24 (1.16–1.33)
Healthcare resource:	S												
LTC beds per 1000, 65 plus Hospital beds per 10000	0.99 (0.99–0.99) 0.98 (0.98–0.98)	1.05 (1.05–1.06) 0.70 (0.70–0.71)	ns ns ns	ns 0.99 (0.99–0.99)	1.01 (1.00–1.01)	υυυ	ns 1.01 (1.00–1.01)	ns S	0.99 (0.98–0.99) ns	1.03 (1.03–1.04) 0.86 (0.85–0.87)	0.998 (0.998–0.999) 0.99 (0.98–0.99)	0.80 (0.79–0.82)	u u u
GPs per 10 000	1.28 (1.26–1.30)	2.69 (2.53–2.86)	1.78 (1.52–2.08)	su	0.88 (0.80-0.96)			su	0.94 (0.91-0.97)	1.76 (1.66–1.87)	0.97 (0.97–0.98)	1.15 (1.14–1.17)	J
Model fit										-			
Nagelkerke R ² (%) Hosmer-Lemeshow test Home death predicted correctly	4.2 <0.01 0.1%	21.1 <0.001 58.2%	8.5 0.037 18.0%	7.6 0.292 2.7%	12.8 0.070 62.4%	1.7 0.273 0.0%	4.6 0.339 0.0%	5.0 0.284 0.0%	5.2 0.020 0.0%	4.6 0.010 0.1%	3.9 <0.001 9.7	10.4 <0.001 83.6	5.3 0.029 0.0
Abbreviations: BE = Belgiurr MX = Mexico; NL = Netherla (10.8% in ES, 41.8% in BE, 1' ^a To construct a parsimoniou	1; CA =Canada; C nd; ns = not signific 1.3% in CZ, 1.5% in s model and select	LI= confidence int cant; NZ= New Ze US, 4% in MX an t the relevant varie	erval; CZ = Czech aland; OR = Odds d 1.9% in KR) and ables for each cou	Republic; ENG ratio; PC = palliat I marital status (3 untry, several alter	= England; ES=S tive care; ref=refei 3% in ES, 2% in M rnative logistic reg	spain; FR = France erence category; U 1X). Cases with mi jression models w	e; GPs=general F IS=United States; issing data were ex vere constructed a	WAL = Wales. Mi walued from the nd evaluated for	ary care physicial ssing data for all v analysis. goodness of fit a	ariables were 0.0–0 ariables were 0.0–0 nd regression diag	is; IT = Italy; KR = S. .6% in all countries e inostics, and a step.	outh Korea; LTC= except for educati vise variable selec	=long-term care; pnal attainment in tion (forward and
to enhance comparability of	the effects betwee	entry and removan	sel al u. Iv. Uniy u	OValiates with 1	ט.טט שפור שפווווייני	י סיו וויכ ו	יבסיים הואפוטוו	צוטוו וווחמבו משויות	ם ממרגאמות החוותי	llofial processes .		regression model	מכוטא נכעוונופי,
⁹ Sample sizes per country n ⁶ NZ: marital status not record	Jay not be equal to Jed on death certifi Jonth contification is	o the total popula ficates and hence r	tion due to missir not included in the	e data for certair model. In the Nt	etherlands marital : etherlands marital :	iables. Cases with status is recorded	as married or not.	e excluded from . Urbanisation in (Canada is coded a	analyses. as urban vs rural. Th immont in Koroo	nere are no long-teri	m care beds in Me	xico. Educational
מומווווופוור ווחר ובתחומבת חוו	Geath Certificates I	וו נומוורבי ואבתובני	arius, Erigiariu, w	ales allo INEW Zec		sepalate categor	y iur iuwer securic	aaly equication to	educational atta				

(Supplementary Table S5, Supplementary Material); (Pastrana et al, 2012; Centeno et al, 2013; Cleary et al, 2013a, b). This suggests that other more complex health or social policy differences, particularly those related to end-of-life cancer care, have a role that cannot easily be captured in a density or availability measure. Past policies could explain why in some countries (France, Spain and Korea), cancer patients were less likely than non-cancer patients to die at home, although cancer patients are often considered as having a more predictable course of disease that increases the chance of a home death (Murtagh et al, 2004). In countries such as France, Spain, Canada and Korea, endof-life cancer care is more often provided in hospital (in palliative care units or other wards) than at home. In France, it appears that there is little support for palliative home care and this carries the risk of aggressive care in the final stages (Observatoire National de la Fin de Vie, 2013). In the Czech Republic, palliative home care is not recognised in the national health insurance law and so provision is low (Slama, 2009). Many patients are thus treated in hospitals, often without palliative care. On the other hand, countries such as the Netherlands (and to a lesser extent the USA) seem to have explicitly chosen to focus on the provision of palliative care at home, which would limit hospital use. England's End-of-life Strategy has a strong focus on primary care and previous research has suggested that it may be the reason for the increased home deaths there (Gao et al, 2013).

It needs to be acknowledged that the place of death patterns we found in people with cancer, as well as the choices in national healthcare organisation that may underlie them, are also the result of historical contingencies and cultural values or circumstances surrounding families and death and dying in the community (Brown and Colton, 2001).

CONCLUSIONS

Where cancer patients die appears to be determined by factors beyond medical necessity or patient characteristics. Countries' healthcare resources, notably availability of hospital beds and long-term care beds, explained part of the country variation in place of death. Healthcare policies specific to end-of-life care likely explain an additional part. This may suggest that choices regarding organising end-of-life cancer care within a society can influence where people receive end-of-life care and die. Further cross-national research applying a more case-oriented qualitative in-depth comparison between a number of relevant comparator countries is needed to understand the reasons behind the differences in place of death.

ACKNOWLEDGEMENTS

We thank the following agencies for the delivery of the death certificate data: Belgium: Flemish Agency for Care and Health, Brussels Health and Social Observatory, French Community of Belgium; France: Inserm-CépiDc (Centre d'épidémiologie sur les causes médicales de décès, Institut national de la santé et de la recherche médicale); Italy: Italian National Institute of Statistics (unit for cause of death statistic); Netherlands: Statistics Netherlands; Spain (Andalusia): Instituto de Estadística y Cartografía de Andalucía; Czech Republic: Institute of Health Information and Statistics of the Czech Republic; Hungary: Central Statistical Office Hungary; USA: Center for Disease Control and Prevention based on Data Use Agreement; Canada: Statistics Canada; New Zealand: New Zealand Ministry of Health; England and Wales: Office for National Statistics; Mexico: Secretaria de Salud and Sistema Nacional de Informacion en Salud; Korea: Statistics Korea. We also thank Jane Ruthven for linguistic help. This work was supported by the Research

Foundation Flanders and the Willy Gepts Fund (Wetenschappelijk Fonds Willy Gepts).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

- Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T (2014) Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. *Arch Intern Med* 164: 545–550.
- Brown M, Colton T (2001) Dying epistemologies: an analysis of home death and its critique. *Environ Plan* 33: 799–821.
- Cárdenas-Turanzas M, Torres-Vigil I, Tovalín-Ahumada H, Nates JL (2011) Hospital versus home death: results from the Mexican Health and Aging Study. J Pain Symptom Manage 41: 880–892.
- Centeno C, Pons JJ, Lynch T, Donea O, Rocafort J, Clark D (2013) *EAPC atlas* of palliative care in Europe Cartographic edition. EAPC Press: Milan.
- Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI (2013a) Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 24(Suppl 1): 41–50.
- Cleary J, Radbruch L, Torode J, Cherny NI (2013b) Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 24(Suppl 1): 24–32.
- Cohen J, Bilsen J, Miccinesi G, Löfmark R, Addington-Hall J, Kaasa S, Norup M, van der Wal G, Deliens L (2007) Using death certificate data to study place of death in 9 European countries: opportunities and weaknesses. *BMC Public Health* 7: 283.
- Cohen J, Houttekier D, Onwuteaka-Philipsen B, Miccinesi G, Addington-Hall J, Kaasa S, Bilsen J, Deliens L (2010) Which patients with cancer die at home? A study of six European countries using death certificate data. J Clin Oncol 28: 2267–2273.
- Davies E, Higginson IJ (2004) *Palliative Care: the Solid Facts*. World Healh Organization: Copenhagen.
- Department of Health (2008) End of Life Care Strategy: Promoting High Quality Care for all Adults at the End of Life London.
- Earle CC (2003) Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data. J Clin Oncol 21: 1133–1138.
- Federale Evaluatiecel Palliatieve Zorg (2008) Evaluatierapport Palliatieve Zorg Brussels.
- Fennell ML (2009) Nursing homes and cancer care. Health Serv Res 44: 1927-1932.
- Gao W, Ho YK, Verne J, Glickman M, Higginson IJ (2013) Changing patterns in place of cancer death in England: a population-based study. *PLoS Med* 10: e1001410.
- Gomes B, Calanzani N, Gysels M, Hall S, Higginson IJ (2013) Heterogeneity and changes in preferences for dying at home: a systematic review. *BMC Palliat Care* **12**: 7.
- Gomes B, Higginson IJ (2006) Factors influencing death at home in terminally ill patients with cancer: systematic review. BMJ 332: 515–521.
- Hantrais L (2008) International Comparative Research: Theory, Methods and Practice. Palgrave Macmillan: Basingstoke, Hampshire, UK.
- Higginson IJ, Sarmento VP, Calanzani N, Benalia H, Gomes B (2013) Dying at home - is it better: a narrative appraisal of the state of the science. *Palliat Med* 27: 918–924.
- House of Commons Health Committee (2004) Palliative Care. Fourth Report of Session 2003–2004, vol. 1.
- Houttekier D, Cohen J, Bilsen J, Addington-Hall J, Onwuteaka-Philipsen BD, Deliens L (2010) Place of death of older persons with dementia. A study in five European countries. J Am Geriatr Soc 58: 751–756.
- Lund JL, Harlan LC, Yabroff KR, Warren JL (2010) Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. *Cancer Invest* 28: 758–764.
- Marie Curie Cancer Care (2012) Understanding the Cost of End of Life Care in Different Settings. Marie Curie Cancer Care: London, UK.
- Murtagh FEM, Preston M, Higginson I (2004) Patterns of dying: palliative care for non-malignant disease. *Clin Med* 4: 39–44.

- O'Sullivan EM (2011) Using epidemiological surveillance systems and routine data sets to study place of care and place of death: strengths and weaknesses. *Palliat Med* **25**: 94–96.
- Observatoire National de la Fin de Vie (2013) Vivre la fin de sa vie chez soi. Observatoire National de la Fin de Vie: Paris, France.
- Pastrana T, De Lima L, Wenk R, Eisenchlas J, Monti C, Rocafort J, Centeno C (2012) Atlas of Palliative Care in Latin America. IAHPC Press: Houston.
- Pennec S, Gaymu J, Monnier A, Riou F, Aubry R, Pontone S, Cases C (2013) Le dernier mois de l'existence: les lieux de fin de vie et de décès en France. *Population* 68(4): 585–615.
- Pivodic L, Higginson IJ, Sarmento VP, Gomes B (2013) Health metrics: standardize records of place of death. *Nature* **495**: 449–449.
- Slama O (2009) [Palliative and hospice care in the Czech Republic and in Europe]. Klin Onkol 22: 183-185.
- Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni T a, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice J a, Peppercorn JM, Somerfield M, Stovall E, Von Roenn JH (2012) American Society of

Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. *J Clin Oncol* **30**: 880–887.

- Van Beek K, Woitha K, Ahmed N, Menten J, Jaspers B, Engels Y, Ahmedzai SH, Vissers K, Hasselaar J (2013) Comparison of legislation, regulations and national health strategies for palliative care in seven European countries (results from the Europall research group): a descriptive study. *BMC Health Serv Res* 13: 275.
- Wright M, Wood J, Lynch T, Clark D (2008) Mapping levels of palliative care development: a global view. J Pain Symptom Manage 35: 469–485.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)